Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
Status:
Unknown status
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine the efficacy and additional advantages of
intravitreal bevacizumab in the treatment of ROP for both Zone I and Zone II Posterior.
Phase:
Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center, Houston